Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;15(9):715-721.
doi: 10.1111/1759-7714.15248. Epub 2024 Feb 16.

Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status?

Shang-Shang Ma  1 , Rang-Rang Wang  1 , Qiao Peng  2 , Yu'e Liu  2 , Jia-Yi Qian  1 , Ming-Jun Li  1 , Kun Li  1 , Zhi-Ye Huang  2 , Lei-Lei Wu  1 , Dong Xie  1
Affiliations

Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status?

Shang-Shang Ma et al. Thorac Cancer. 2024 Mar.

Abstract

Background: The data of the prognostic role of V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations in early-stage lung adenocarcinoma (LUAD) patients is scarce. This study aimed to investigate the proportion, clinicopathological features, and prognostic significance of patients with stage I LUAD carrying BRAF mutations.

Methods: We collected 431 patients with pathological stage I LUAD from cBioPortal for Cancer Genomics and 1604 LUAD patients tested for BRAF V600E and epidermal growth factor receptor (EGFR) mutations from Shanghai Pulmonary Hospital. Survival curves were drawn by the Kaplan-Meier method and compared by log-rank test. Cox proportional hazard models, propensity-score matching (PSM), and overlap weighting (OW) were performed in this study. The primary endpoint was recurrence-free survival (RFS).

Results: The proportion of BRAF mutations was estimated at 5.6% in a Caucasian cohort. BRAF V600E mutations were detected in six (1.4%) patients in Caucasian populations and 16 (1.0%) patients in Chinese populations. Two BRAF V600E-mutant patients were detected to have concurrent EGFR mutations, one for 19-del and one for L858R. For pathological stage I LUAD patients, BRAF mutations were not significantly associated with worse RFS than wild-type BRAF patients (HR = 1.111; p = 0.885). After PSM and OW, similar results were presented (HR = 1.352; p = 0.742 and HR = 1.246; p = 0.764, respectively). BRAF V600E mutation status also lacked predictive significance for RFS (HR, 1.844; p = 0.226; HR = 1.144; p = 0.831 and HR = 1.466; p = 0.450, respectively).

Conclusions: In this study, we demonstrated that BRAF status may not be capable of predicting prognosis in stage I LUAD patients. There is a need for more data to validate our findings.

Keywords: BRAF V600E mutations; lung adenocarcinoma; overlap weighting; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

FIGURE 1
FIGURE 1
The flow chart of patient selection from cBioPortal for Cancer Genomics (a) and Shanghai Pulmonary Hospital (b).
FIGURE 2
FIGURE 2
Kaplan–Meier survival curves for patients with lung adenocarcinoma in cohort 1. recurrence‐free survival before (a) matching, (b) after propensity‐score matching (PSM), and (c) after overlap weighting (OW).
FIGURE 3
FIGURE 3
Kaplan–Meier survival curses for patients with lung adenocarcinoma in cohort 2. Recurrence‐free survival before (a) matching, (b) after propensity‐score matching (PSM), and (c) after overlap weighting (OW).
FIGURE 4
FIGURE 4
Mutation spectrum based on BRAF mutation class in 41 ADC patients.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca‐Cancer J Clin. 2021;71(3):209–249. - PubMed
    1. Tabbo F et al. How far we have come targeting BRAF‐mutant non‐small cell lung cancer (NSCLC). Cancer Treat Rev. 2022;103:102335. - PubMed
    1. Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, et al. BRAF in non‐small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev. 2018;66:82–94. - PubMed
    1. Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611–625. - PubMed
    1. Riudavets M, Cascetta P, Planchard D. Targeting BRAF‐mutant non‐small cell lung cancer: current status and future directions. Lung Cancer. 2022;169:102–114. - PubMed

Publication types